Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Science Group further increases stake in Ricardo

(Sharecast News) - Science Group announced on Friday that it has further increased its stake in Ricardo to 19.09%, intensifying pressure on the engineering consultancy's board following a series of scathing critiques of its governance and strategic decisions. The enlarged holding, equivalent to 11.88 million shares, was acquired at an average cost of 235p per share, and made Science Group Ricardo's second largest shareholder.

Its move followed a sharply worded statement issued by Science Group earlier in the week, in which it expressed deep concern over Ricardo's financial performance, governance standards, and recent strategic actions.

In that statement, Science Group accused Ricardo's board of failing to deliver on previously stated profit targets and allowing operational inefficiencies, including poor cost control and weak cash conversion, to erode shareholder value.

Science Group, which noted that it had consistently outperformed Ricardo on key financial metrics, argued that the latter's underperformance could not be blamed solely on external market conditions.

It highlighted its own robust margins, strong earnings growth, and disciplined capital management as evidence that Ricardo's challenges stem from internal failings.

The group also renewed criticism of executive remuneration at Ricardo, calling it disproportionate given the company's declining market value.

It pointed to the board's minimal shareholdings as further evidence of misalignment with shareholder interests and reiterated its demand that no further acquisitions or disposals occur without shareholder approval.

The call came amid speculation that Ricardo may be preparing to sell its performance products division.

Particularly contentious was Ricardo's recent Australian acquisition, completed just weeks before a profit warning in January.

Science Group described the timing as reckless and symptomatic of deeper governance problems, asserting that a fundamental change in oversight was required.

It also dismissed Ricardo's objections to its own board nomination efforts, saying its involvement would strengthen - not dominate - corporate governance.

Despite Ricardo's stated intention to publish a new strategic update in mid-April, Science Group questioned the board's credibility and execution track record, concluding that a leadership change at the top was necessary.

Ricardo was yet to issue a substantive response to the issues raised across Science Group's announcements.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.